CYTK Overview
Upcoming Projects (CYTK)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (CYTK)
-
A Third Look: Discussing the latest results from the Phase 3 SEQUOIA-HCM trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
Ticker: CYTK
Executed On: May 31, 2024 at 09:15 AM EDT -
A Second Look: Discussing the latest results from the Phase 3 SEQUOIA-HCM trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
Ticker: CYTK
Executed On: May 17, 2024 at 03:00 PM EDT -
Discussing the latest results from the Phase 3 SEQUOIA-HCM trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
Ticker: CYTK
Executed On: May 17, 2024 at 02:00 PM EDT -
A Third look at Viz.AIs new artificial intelligence algorithm for earlier detection and management of hypertrophic cardiomyopathy
Tickers: VIZ.AI, BMY, CYTK
Executed On: Feb 28, 2024 at 08:30 AM EST -
A Second look at Viz.AIs new artificial intelligence algorithm for earlier detection and management of hypertrophic cardiomyopathy
Tickers: VIZ.AI, BMY, CYTK
Executed On: Jan 26, 2024 at 08:30 AM EST -
A look at Viz.AIs new artificial intelligence algorithm for earlier detection and management of hypertrophic cardiomyopathy
Tickers: VIZ.AI, BMY, CYTK
Executed On: Jan 25, 2024 at 04:00 PM EST -
A Third Look: Investigating the topline results from the phase 3 SEQUOIA-HCM clinical trial of Aficamten in patients with Obstructive Hypertrophic Cardiomyopathy
Ticker: CYTK
Executed On: Jan 24, 2024 at 04:45 PM EST -
A Second Look: Investigating the topline results from the phase 3 SEQUOIA-HCM clinical trial of Aficamten in patients with Obstructive Hypertrophic Cardiomyopathy
Ticker: CYTK
Executed On: Jan 24, 2024 at 04:00 PM EST -
Investigating the topline results from the phase 3 SEQUOIA-HCM clinical trial of Aficamten in patients with Obstructive Hypertrophic Cardiomyopathy
Ticker: CYTK
Executed On: Jan 10, 2024 at 12:45 PM EST -
A Third Look: Discussing aficamten for patients with obstructive hypertrophic cardiomyopathy (oHCM) in the phase 3 SEQOUIA-HCM trial
Ticker: CYTK
Executed On: Nov 30, 2023 at 08:45 AM EST -
A Second Look: Discussing aficamten for patients with obstructive hypertrophic cardiomyopathy (oHCM) in the phase 3 SEQOUIA-HCM trial
Ticker: CYTK
Executed On: Nov 29, 2023 at 01:00 PM EST -
Discussing aficamten for patients with obstructive hypertrophic cardiomyopathy (oHCM) in the phase 3 SEQOUIA-HCM trial
Ticker: CYTK
Executed On: Nov 09, 2023 at 02:30 PM EST -
A Third Look: Digging into the Phase 2 clinical trial results of aficamten in patients with non-obstructive hypertrophic cardiomyopathy
Ticker: CYTK
Executed On: Mar 16, 2023 at 11:00 AM EDT -
Digging into the Phase 2 clinical trial results of aficamten in patients with non-obstructive hypertrophic cardiomyopathy
Ticker: CYTK
Executed On: Mar 15, 2023 at 06:30 PM EDT -
A Second Look: Digging into the Phase 2 clinical trial results of aficamten in patients with non-obstructive hypertrophic cardiomyopathy
Ticker: CYTK
Executed On: Mar 15, 2023 at 05:30 PM EDT -
A Second Look: Discussing omecamtiv mecarbil (investigational small molecule cardiac myosin activator) for the treatment of HFrEF
Ticker: CYTK
Executed On: Feb 02, 2023 at 03:00 PM EST -
Discussing omecamtiv mecarbil (investigational small molecule cardiac myosin activator) for the treatment of HFrEF
Ticker: CYTK
Executed On: Jan 26, 2023 at 10:00 AM EST
Upcoming & Overdue Catalysts (CYTK)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (CYTK)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
